An investment adviser reports a passive stake above 5% in Faeth Therapeutics (FTH).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a passive stake of 5.46% in Faeth Therapeutics, Inc. (FTH), through a SCHEDULE 13G SEC filing. This represents 1,410,000 beneficially owned shares, acquired for investment purposes on behalf of Avoro Life Sciences Fund LLC. The reported ownership is based on 25,840,425 common shares outstanding as of July 30, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.